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Summary
Fibroblast heterogeneity has been recognized for decades, but the basis for
multiple phenotypes among these cells has been investigated only recently.
More than 15 years ago, Bucalla and his colleagues described for the first time
a population of fibroblast-like cells among circulating mononuclear blood
cells. Subsequently these mesenchymal cells, termed fibrocytes, have been
characterized and found to participate in normal and pathological tissue
remodelling. In this review, I have attempted to present the evidence gener-
ated thus far suggesting that fibrocytes are participants in autoimmune dis-
eases where tissues are injured and undergo remodelling. Aspects of their
phenotype suggest that they are well suited to help orchestrate immune
responses through mononuclear cell recruitment and their ability to produce
inflammatory mediators and extracellular matrix molecules. These attributes
also raise the possibility that they might be useful targets against which thera-
peutic agents might be aimed.
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Fibroblast heterogeneity has been appreciated for several
decades but its biological significance and the basis for cel-
lular diversity remain uncertain. The question of why fibro-
blasts from distant anatomical regions should exhibit
phenotypic divergence is unanswered. Moreover, a mecha-
nism that might account for dissimilar fibroblasts inhabiting
specific tissues has not been identified. Three connective
tissue depots from which fibroblasts have been studied with
considerable rigour include lung, joint and orbital connec-
tive tissue [1–4]. The origins and phenotypic characteristics
of the fibroblasts found in these tissues have become increas-
ingly important as investigation into the nature of organ-
specific autoimmune diseases proceeds. The concept that
localization of systemic diseases could result, at least in part,
from the peculiarities exhibited by fibroblasts in affected
tissues continues to attract substantial discussion. However,
significant advances have been made recently in our ability
to distinguish between similarly appearing cells with
‘fibroblast-like’ morphologies. Despite these new insights,
substantial imprecision persists in identifying the diverse
biological roles of cells that resemble each other. At the heart
of the problem lingers the absence of a single, specific marker
that could distinguish fibroblasts from all other cells. Once
characterized, such a protein would undoubtedly prove
invaluable in elucidating more clearly the molecular mecha-
nisms and cellular interactions that underlie normal and
pathological tissue remodelling.
The orbital fibroblast: an example of
cellular diversity
Orbital fibroblasts comprise a heterogeneous population of
cells that can be separated into discrete subsets based on their
display of surface markers [5]. The most frequently studied
of these is Thy-1, which has been used by several investiga-
tors to discriminate between those fibroblasts that can dif-
ferentiate into myofibroblasts (Thy-1+) and those capable of
becoming adipocytes (Thy-1-) [6,7]. This assignment is also
true for fibroblasts from lung [8,9]. When Thy-1+ fibroblasts
are exposed to transforming growth factor (TGF)-b, they
differentiate into myofibroblasts. In contrast, Thy-1-
fibroblasts terminally differentiate into adipocytes when
proliferator-activated receptor (PPAR)g is activated with
prostaglandin J2 or thiazolidinediones such as rosigli-
tazone. Whether these distinctions hold true for cells
in vivo is not yet known. The basis for the cellular diversity
observed in these connective tissue depots has yet to be
determined, but may ultimately explain the patterns of tissue
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remodelling observed in both anatomic regions. With regard
to the orbit, the potential for Thy-1- fibroblasts to differen-
tiate into adipocytes might help to explain the apparent
expansion of fat found in Graves’ disease.
Infiltration of fibrocytes into tissues might
contribute to apparent fibroblast diversity
Fibrocytes represent circulating bone-marrow derived
monocyte lineage cells that present antigen efficiently to
lymphocytes, prime naive T cells and can enter sites of tissue
injury [10,11]. They are distinct from fibroblasts, T and B
lymphocytes, monocytes, epithelial, endothelial and den-
dritic cells and can differentiate into mature fat cells, osteo-
blasts and myofibroblasts. Their ultimate fate depends, at
least in part, upon the signals they receive from their
microenvironment and which of the intracellular
signalling pathways become activated [12]. In this regard,
fibrocytes resemble fibroblasts. Fibrocytes were first
described by Bucalla et al. in 1994 as possessing a
CD34+vimentin+collagen+ phenotype [10], They were found
capable of circulating as members of a population of periph-
eral blood mononuclear cells and were shown to enter
wound chambers implanted in subcutaneous tissue. They
were identified in connective tissue scars. Once fibrocytes
have infiltrated injured target tissues undergoing remodel-
ling, they assume a fibroblast-like morphology. Moreover,
they appear to lose their surface expression of CD34 as they
develop into fibroblasts [13], suggesting that this protein
behaves as a progenitor marker. Fibrocytes are believed to
interact with other mononuclear cells that have also been
recruited from the circulation. They can also cross-talk with
residential fibroblasts. Currently it is uncertain exactly what
roles fibrocytes play in tissue regeneration or how they might
participate in the formation of fibrosis. Moreover, the
mechanisms and signalling pathways through which they
exchange molecular information with other cells are only
partially identified. A major hurdle in characterizing fibro-
cytes and distinguishing them from fibroblasts continues to
result from the absence of specific surface markers. Identifi-
cation of fibrocytes as a distinct cell type has resulted from a
rigorous set of characterization studies which should now
allow greater precision in classifying their biological func-
tions and attributing them to specific subpopulations of
cells.
Characterization of the fibrocyte phenotype
Initial studies examining the phenotype of fibrocytes
involved observations made following their initiation and
propagation in cell culture. Subsequently, their activities
have been described in vivo. Much of what we now
know about their behaviour has been generated in animal
models. In mice, fibrocytes appear to develop from
CD115+CD11b+Gr1+ monocytes. When mouse splenocytes
were cultured for 14 days, Niedermeier et al. [14] found an
outgrowth of spindle-shaped cells. When analysed by flow
cytometry, they appear as collagen I-expressing cells which
also display a CD45+CD11b+CD16/32+ phenotype but lack
CXCR4, CD34 or CD115 expression. When depleted of
certain leucocyte subsets such as CD11b+, CD115+, CD16/32+
or Gr1+, considerably fewer fibrocytes are generated. A
number of factors extrinsic to fibrocytes have been impli-
cated in their regulation. Of particular interest, the study by
Niedermeier et al. demonstrated that CD4+ lymphocytes
support fibrocyte differentiation [14]. The presence of non-
activated CD4+ cells substantially enhances fibrocyte in vitro.
Conversely, the absence of these lymphocytes reduces differ-
entiation, both in vitro and in vivo. When activated, CD4+ T
cells release TNF-a, interleukin (IL)-4, interferon (IFN)-g,
and IL-2. The fibrosis induced by unilateral ureteral obstruc-
tion can be reduced substantially by IL-2 and TNF-a, as can
the appearance of fibrocytes. When CD4+ cells undergo acti-
vation in the presence of calcineurin inhibitors such as
cyclosporin, they promote collagen deposition and enhance
fibrocyte accumulation in this model. Why fibrocytes are
induced to infiltrate kidneys following unilateral ureteral
obstruction, but are relatively rare in renal tissues from simi-
larly manipulated severe combined immunodeficiency
(SCID) mice, might be attributable to the absence of lym-
phocytes in immunodeficient animals.
A recent study by Pilling et al. [15] has examined the
markers that might be useful in distinguishing human fibro-
cytes from fibroblasts. In their remarkably detailed and
exhaustive study, the authors found that among the cell
types examined, only fibrocytes express the combination of
CD45RO, 25F9 and S100A8/A9. They included in their study
fibroblasts, macrophages and peripheral blood monocytes.
Importantly, they concluded that CD34, CD68 and collagen
fail to discriminate among these four cell types. Several
cytokines, including IFN-g, IL-4, IL-12, IL-13 and serum
amyloid P, differentially affect the display of CD32, CD163,
CD172a and CD206 in fibrocytes and macrophages [15].
Human fibrocytes express a diverse array of cytokines,
including TNF-a, IL-1b, IL-10, monocyte chemoattractant
protein (MCP), macrophage inflammatory protein
(MIP)-1a, MIP-1b, MIP-2, platelet-derived growth factor
(PDGF)-A, TGF-b1 and macrophage colony-stimulating
factor (M-CSF). Moreover, treatment of fibrocytes with
exogenous IL-1b induced IL-6, IL-8, IL-10, MCP-1, MIP-1a
and MIP-1b. Thus the array of cytokines produced by fibro-
cytes, either under basal conditions or following activation
by IL-1b, appears to be very similar to that found in fibro-
blasts originating from a variety of tissues.
Regulation of fibrocyte trafficking to sites of injury and
tissue repair apparently derives from a network of chemok-
ines and chemoattractants. CXCR4 represents the principal
chemokine receptor displayed on human fibrocytes. Its
cognate ligand, CXCL12, is generated by several cell types.
CXCL12 has been shown in several models to exert powerful
Fibrocytes in autoimmune disease
25© 2010 The Authors
Clinical and Experimental Immunology © 2010 British Society for Immunology, Clinical and Experimental Immunology, 162: 24–31
chemotactic influence by fibrocytes and represents a major
determinant for their infiltration of target tissues. In addi-
tion, CCR3, CCR5 and CCR7 are also expressed on the
human fibrocyte surface [16,17]. A slightly different profile
of receptors is found on animal fibrocytes. For instance,
mouse fibrocytes display CXCR4, CCR2 and CCR7. PDGF,
insulin-like growth factor (IGF) and epidermal growth
factor (EGF) can induce CXCR4 mRNA [18]. Growth factor
and hypoxia-driven CXCR4 display is mediated through the
PI3 kinase/mTor pathway and can be inhibited by rapamy-
cin, which substantially diminished the accumulation of
fibrocytes in targeted tissues.
Evidence for fibrocyte involvement in
human diseases
In the last few years, more attention has been focused upon
the study of human fibrocytes and their potential abnor-
malities in disease. The research group led by Streiter has
produced substantial evidence for fibrocytes playing an
important role in lung fibrosis. In a series of reports, these
investigators have demonstrated the remarkable plasticity
with which fibrocytes can differentiate into either adipocytes
or myofibroblasts, depending upon whether they are treated
with an activator of PPARg or TGF-b [12,19]. With regard to
the former, troglitazone treatment resulted in the accumula-
tion of lipid within the cytoplasm and the induction of
the adipocyte-specific gene aP2. In contrast, activation
of Smad2/3 and stress-activated protein kinase/c-Jun
N-terminal kinase mitogen-activated protein kinase path-
ways results in the transition of fibrocytes to myofibroblasts
and the induction of a-smooth muscle actin. The potential
for fibrocyte participation in autoimmune disease remains
relatively unexplored. Bohle and co-workers [20] examined
the pathogenic basis for chronic renal failure developing as a
consequence of primary glomerulopathies. They reported
that renal insufficiency can result from chronically inflamed
renal cortical post-glomerular capillaries. Vessel narrowing
can impair glomerular perfusion. The authors found evi-
dence suggesting that material reabsorbed by tubules could
then be presented as autoantigens to intraepithelial T cells,
leading potentially to immune responses involving expanded
numbers of fibroblasts and fibrocytes. In an attempt to deter-
mine the propensity of marmosets to autoimmune disease,
Maile and Merker described the tissue architecture of the
thyroid [21]. They found monocytes, macrophages, mast
cells and fibrocytes and speculated that these cells participate
in the frequent thyroid autoimmunity found in these
animals. Using phospho-specific flow cytometry, Galligan
et al. examined peripheral blood fibrocytes from patients
with established rheumatoid arthritis of greater than 1 year
duration [22]. They reported that both p44/42 extracellular
regulated (Erk) and p38 arms of the mitogen-activated
protein kinase (MAPK) pathway were activated in these
fibrocytes, as were signal transducer and activator of tran-
scription (STAT) 3 and STAT5. The levels of phosphoryla-
tion found in early versus established rheumatoid arthritis
were similar, suggesting that the levels of signalling might
prove invariant following disease initiation. In a mouse
model of sclerosing cholangitis, designated Abcb-/-, Roder-
feld and colleagues were able to demonstrate the involve-
ment of both bone marrow-derived fibrocytes and hepatic
stellate cells in biliary fibrogenesis [23].
Fibrocytes have been implicated in wound healing. This
process is accelerated in mice deficient in leucocyte-specific
protein 1 (LSP-1) [24], a molecule purported to represent
a reliable fibrocyte marker. It was also suggested that LSP-1
display might help to discriminate fibrocytes from fibroblasts
[25]. LSP-1 null mice were found to have increased levels of
macrophages, neutrophils and fibrocytes in full-thickness
skin wounds. These tissues were also found to have elevated
levels of TGF-b and vascular endothelial growth factor
(VEGF) [24]. Similarly, bleomycin-induced fibrosis of the
skin was enhanced in Lsp-/- mice [26]. Fibrocytes from
patients with thermal burns and those from normal donors
have substantially less capacity for collagen production than
do dermal fibroblasts [27]. When conditioned medium from
fibrocytes derived from burned individuals was incubated
with dermal fibroblasts, they exhibited accelerated prolifera-
tion when compared to those incubated in medium from
control fibrocytes. These effects could be blocked with TGF-b
neutralizing antibodies [27]. These same investigators have
shown that IFN-a2b can reduce scar formation following
thermal injury by attenuating fibrocyte activity and reducing
their numbers [28].
With regard to the kidney, the participation of bone
marrow-derived stem cells remains controversial [29].
Results generated in a number of models of renal injury
suggest that these stem cells can localize to specific areas of
the kidney and might facilitate tissue regeneration. Thus,
their therapeutic potential in several forms of human
kidney dysfunction is under evaluation. The outcome of
such studies will probably influence the research being con-
ducted in allied disease processes involving other organs
and tissues.
Graves’ disease as a model of fibrocyte
participation in human autoimmunity: basis for
orbital fibroblast heterogeneity?
Graves’ disease represents an autoimmune process where the
thyroid becomes enlarged and overactive [30]. The basis for
the over-production of thyroid hormones and gland enlarge-
ment in this disease involves the production and activity of
autoantibodies targeting the thyrotrophin (aka thyroid-
stimulating hormone) receptor (TSHR). In addition, the
IGF-1 receptor (IGF-1R) is over-expressed by orbital fibro-
blasts [31], B [32] and T cells [33,34] in patients with the
disease. IGF-1R represents a second potentially pathogenic
autoantigen that may account for abnormal thyroid
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enlargement and underlie the trafficking of lymphocytes to
affected tissues, including the pretibial skin and orbit. Prit-
chard et al. [31] have suggested that T cell trafficking to the
orbit in Graves’ disease might be mediated through fibroblast
responses to IGF-1 and Graves’ disease-immunoglobulin G
(GD-IgG). When exposed to either agent, these fibroblasts
express high levels of the T cell chemoattractants, IL-16 and
regulated on activation normal T cell expressed and secreted
(RANTES). The fibroblast response is mediated through
IGF-1R activation and post-receptor signalling through the
FRAP/mTor/Akt/p70s6k pathway. It is absent in fibroblasts
derived from healthy donors [35]. In addition to the genera-
tion of chemoattractants, thyroid-associated ophthalmopa-
thy (TAO) orbital fibroblasts synthesize high levels of
hyaluronan, in response to either GD-IgGs or IGF-1. Hyalu-
ronan is a non-sulphated glycosaminoglycan, the accumula-
tion of which is thought to result in tissue oedema [36].
Orbital connective tissue derives in large part from neural
ectoderm [37]. This tissue has a special propensity for
inflammation. Approximately 30% of those individuals with
Graves’ disease also develop clinically important involve-
ment of the orbit tissues surrounding the eye, a manifesta-
tion referred to as TAO. In this connective tissue component,
the orbit becomes inflamed, and infiltrated with T and B
lymphocytes and mast cells [38]. The cytokines and disease-
mediating factors generated by these infiltrating cells are
currently thought to activate resident fibroblasts which
exhibit a unique phenotype. Orbital fibroblasts comprise a
heterogeneous population of cells, especially those derived
from patients with TAO [39]. The cellular attributes peculiar
to orbital fibroblasts are thought to underlie the susceptibil-
ity of the orbit to the manifestations of Graves’ disease.
For instance, these fibroblasts exhibit particularly robust
responses to proinflammatory cytokines such as the
members of the IL-1 family. When activated by IL-1b, leu-
coregulin or CD154, orbital fibroblasts, especially those from
patients with TAO, produce unusually high levels of hyalu-
ronan [40]. This results from the induction of hyaluronan
synthase (HAS) 1, 2 and 3 [41] and uridylyltransferase
(UDP) glucose dehydrogenase [42]. The exaggerated induc-
tion of HAS isoforms could therefore account for the accu-
mulation of hyaluronan in TAO. Activated orbital fibroblasts
also express extremely high levels of IL-6, IL-8 and the pros-
taglandin endoperoxide H synthase-2, the inflammatory
cyclooxygenase [43,44]. This latter induction, in turn, results
in the production of extraordinarily high levels of prostag-
landin E2 (PGE2) [45]. The prostanoid can exert an impor-
tant bias on immune responses occurring in the orbit and
favour T helper type 2 (Th2) predominance [46]. The mag-
nitude of the induction of proinflammatory cytokines by
orbital fibroblasts is remarkable but poorly understood. Cao
and Smith reported the relatively low levels of secreted IL-1
receptor antagonist (IL-1RA) produced by these cells [47].
Low levels of IL-1RA generation achieved following expo-
sure to IL-1b results in poorly opposed IL-1a and IL-1b
initiated signalling. Thus, the amplitude of cytokine-
provoked downstream gene expression is substantially
greater than that achieved in other fibroblast types.
Fig. 1. CD34+LSP-1+ TSHR+ fibrocytes can be identified in the orbital tissue of patients with TAO but are absent in tissues from healthy donors. (a)
CD34 expression (arrows, green FITC) in TAO-derived tissue (inset, negative control staining). (b) Absent CD34 expression in healthy tissue (inset,
positive staining control). (c) LSP-1 expression in TAO-derived tissue [red, arrows, nuclei counterstained with DAPI (blue)] (inset negative control).
(d) Absence of LSP-1 expression in healthy tissue (inset negative control). (e) CD31 expression in disease-derived tissue is limited to vascular
endothelium (red, arrows). (f) H and E stained consecutive thin-sections of the same orbital tissue (40¥). (g) Fibrocytes present in orbital tissue
from patients with TAO co-express CD34 and TSHR. Nuclei were counterstained with DAPI (blue). Thin sections were then subjected to confocal
microscopy. Inset contains a negative staining control. (Reprinted with permission; Douglas, RS et al. Increased generation of fibrocytes in
thyroid-associated ophthalmopathy, Copyright 2010, The Endocrine Society.)
Fibrocytes in autoimmune disease
27© 2010 The Authors
Clinical and Experimental Immunology © 2010 British Society for Immunology, Clinical and Experimental Immunology, 162: 24–31
The basis for the heterogeneity displayed by orbital fibro-
blasts is yet to be understood [48]. When sorted on the basis
of whether or not they display Thy-1 (CD90), orbital fibro-
blasts can be categorized broadly as those possessing the
potential to become adipocytes (Thy-1-) and those that can
differentiate into myofibroblasts (Thy-1+) subsets [6]. Fibro-
blasts destined to become fat cells can do so spontaneously in
culture or more efficiently when treated with prostacyclin
together with compounds that increase intracellular cyclic
adenosine-5′-monophosphate (cAMP) levels or with mol-
ecules that bind and activate PPAR g [6,7]. Conversely,
Thy-1+ fibroblasts differentiate into myofibroblasts that
express high levels of smooth muscle actin. This occurs fol-
lowing their exposure to TGF-b. Accompanying their tran-
sition to adipocytes, levels of TSHR are increased
substantially [49], but what fibroblast subsets display TSHR
specifically, and are these receptor molecules functional?
Douglas and colleagues [50] have reported very recently
that the frequency of fibrocytes circulating in patients with
Graves’ disease is elevated above the levels found in healthy
individuals. As others have reported previously, this study
suggested that fibrocyte generation from cultured peripheral
blood mononuclear cells (PBMCs) derived from donors
without any known chronic diseases were vanishingly rare.
In contrast, cultured PBMCs from many patients with
Graves’ disease, regardless of duration, thyroidal status or
treatment received, generated numerous fibrocytes that
exhibited the expected CD34+Col1+CXCR4+ phenotype.
Interestingly, the elevated frequency of fibrocyte generation
was not universal among patients with the disease. Many of
these individuals, even those with recent onset and clinically
severe disease, failed to generate fibrocytes at levels differing
from those found in the control donors. The authors found
relatively high levels of IGF-1R on fibrocytes, but the levels
appear to be no different from those on fibrocytes donated
by control subjects.
The report by Douglas et al. [50] began to characterize the
phenotypic attributes of fibrocytes found in Graves’ disease.
Those studies aimed at identification of those cellular features
that might underlie their participation in TAO. The authors
found that CD34+Col1+IGF-1R+ cells were relatively abun-
dant in situ in orbital tissue from patients with TAO but were
absent in those from healthy donors (Fig. 1). They were con-
sistently CD31-, indicating that the putative fibrocytes were
unrelated to endothelial cells. Surprisingly, high levels of
TSHR were detected on the circulating fibrocyte surface. The
levels of this protein appear equivalent to those found on
thyroid epithelial cells, where they mediate thyroid hormone
production (Fig. 2). Even more surprising was their observa-
tion that the receptor is functional. When ligated with bovine
thyroid-stimulating hormone (bTSH) or M22, an activating
monoclonal antibody generated against TSHR, the produc-
tion of inflammatory cytokines such as TNF-a and IL-6 is
up-regulated dramatically (Fig. 3) [50]. When orbital fibro-
blasts from patients with TAO were subjected to flow cyto-
metric analysis, a subpopulation of cells was found to exhibit
the CD34+Col1+ phenotype. In contrast, CD34+ cells were
uniformly absent among orbital fibroblasts from control
donors. This phenotype was stable in culture over many serial
passages. Moreover, it appears that the vast majority of CD34+
orbital fibroblasts are also CD90+ (Thy-1+).
The finding that fibrocytes express high levels of TSHR
and IGF-1R, coupled with their display of human leucocyte
antigen D-related (HLA-DR), suggests that they might
present autoantigens efficiently to T cells and in so doing
could initiate antigen-specific immune responses. If this
proves to be the case, the fibrocyte might represent an effec-
tive therapeutic target for early Graves’ disease. As the phe-
notype of these cells becomes characterized more rigorously















Fig. 2. Fibrocytes cultivated from peripheral blood mononuclear cells
(PBMCs) express high levels of thyroid-stimulating hormone receptor
(TSHR) regardless of whether they derive from (a) patients with
Graves’ disease or (b) healthy donors. (c) These levels are comparable
to those found on primary human thyroid epithelial cells. (d) In
contrast, undifferentiated orbital fibroblasts fail to express TSHR. (e)
Fibrocytes differentiated into adipocytes accumulate intracellular lipid
droplets staining with Oil Red O. (f) TSHR levels on fibrocytes
remain elevated following differentiation. In (a), fibrocytes were
preincubated with bovine thyroid-stimulating hormone (bTSH)
(5 mU/ml) prior to staining with anti-TSHR antibodies. (Reprinted
with permission; Douglas, RS et al. Increased generation of fibrocytes
in thyroid-associated ophthalmopathy, Copyright 2010, The
Endocrine Society.)
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becomes identified, it may be possible to target them with
specific molecular probes. This strategy could yield individu-
alized therapies.
Conclusions
The involvement of the orbit in Graves’ disease can serve as
a potentially important model for fibrocyte behaviour in
autoimmune diseases. Moreover, the cellular diversity found
among fibroblasts inhabiting the human orbit might, at least
in part, be reconciled by the recruitment of fibrocytes and
their differentiation into cells exhibiting distinct phenotypes.
A schematic of our theoretical model for TAO and the puta-
tive involvement of fibrocytes in that disease process are
presented in Fig. 4. Orbital fibroblast diversity and their
remarkable divergence from the phenotype more typically
exhibited by fibroblasts from other tissues can, for the first
time, be explained on the basis of their potential derivation
from bone marrow-derived precursors. It is possible that this
subset of fibroblasts is trafficked specifically to the orbit in
TAO as a consequence of as-yet unidentified initiating

























































Fig. 3. Thyroid-stimulating hormone receptor (TSHR) displayed on fibrocytes generated from peripheral blood mononuclear cells (PBMCs)
can function to initiate cytokine production. Cultured cells, in this case from a patient with Graves’ disease, were treated with bovine
thyroid-stimulating hormone (bTSH) (5 mU/ml) or interleukin (IL)-1b (10 ng/ml) for 48 h. The medium was subjected to enzyme-linked
immunosorbent assays specific for (a) IL-6 or (b) tumour necrosis factor (TNF)-a. Data are expressed as the mean  standard error of the mean of
three replicate culture wells from a representative experiment (*P < 0·001). (Reprinted with permission; Douglas, RS et al. Increased generation of
fibrocytes in thyroid-associated ophthalmopathy, Copyright 2010, The Endocrine Society.)
Fig. 4. Theoretical model of orbital fibroblast
derivation and the molecular events occurring
in thyroid-associated ophthalmopathy (TAO).
HAS, hyaluronan synthase; TSHR, thyroid
stimulating hormone receptor; IGF-1R,
insulin-like growth factor-1 receptor; Col1,
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for differentiation into either adipocytes or myofibroblasts
may underlie the characteristic tissue remodelling that
occurs in the disease. The relative frequency of fibrocytes and
the phenotypic peculiarities exhibited by them could poten-
tially explain why expansion of orbital fat might dominate
the pathology of some patients with TAO while others mani-
fest muscle-predominant disease. Moreover, identifying
fibrocytes as playing a pathogenic role in TAO might allow
them to be targeted by therapeutic agents, a strategy which
has been proposed previously for other diseases involving
tissue remodelling and fibrosis [17]. Layered onto these char-
acteristics is the recent finding that TSHR is expressed at
relatively high levels by these cells. This disease-specific
autoantigen is functional in fibrocytes and could mediate
cytokine production as a consequence of the activating
autoantibodies directed against TSHR that are also respon-
sible for the overactive thyroid in Graves’ disease. This brings
to light another heretofore unanticipated potential role for
fibrocytes. Could these cells participate in the breakdown of
immune tolerance of TSHR? Alternatively, could display of
this protein on the surface of fibrocytes function to enhance
peripheral tolerance? The recent findings by Douglas and
colleagues suggest a number of testable hypotheses and
could ultimately provide the overarching framework
for Graves’ disease and potentially other forms of
autoimmunity.
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